Vol. 2 No. 6 (2022): June
Reimbursement Reviews

Prasterone (Intrarosa)

Published June 17, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses prasterone (Intrarosa) 6.5mg ovule, administered intravaginally.
  • Indication: Prasterone is indicated for the treatment of post-menopausal vulvovaginal atrophy.